<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03004079</url>
  </required_header>
  <id_info>
    <org_study_id>19259</org_study_id>
    <nct_id>NCT03004079</nct_id>
  </id_info>
  <brief_title>Clinical Importance of Glucose Regulation in Relapsing MS</brief_title>
  <official_title>Assessment of the Clinical Importance of Insulin Resistance &amp; Steroid-Associated Hyperglycemia in Relapsing Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Multiple Sclerosis Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the relationship of blood glucose levels in persons
      with Multiple Sclerosis (MS) who have experienced a relapse and will be receiving intravenous
      steroids for the relapse, to their recovery from the relapse.

      Steroid exposure commonly leads to elevated serum blood glucose, however, standardized
      monitoring of blood glucose levels in the outpatient setting is not common. The clinical
      impact of any associated elevated blood glucose during steroid administration is unknown. We
      hypothesize that the blood glucose response to steroid treatment is clinically relevant to
      the MS-relapse recovery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple Sclerosis (MS) is a neuroinflammatory and degenerative central nervous system
      disorder. The majority of patients have an early relapsing-remitting course. Standard
      treatment for an MS-relapse is intravenous methylprednisolone (IVMP), typically 1000 mg daily
      for 3 days. Despite IVMP treatment, &gt;40% of MS patients experience residual deficits after an
      MS-relapse. Potential risk factors for poor relapse recovery remain unclear.

      Elevated serum blood glucose is a common and well-defined consequence of steroid
      administration, attributed to steroid-related reductions in insulin sensitivity. Individuals
      with pre-treatment insulin resistance (e.g. diabetics) will exhibit an amplified
      hyperglycemic response. Reduced mobility, sedentary lifestyle, and repeated exposure to
      steroids- all of which are common in MS - are recognized risk factors for insulin resistance.
      These factors may make MS patients particularly susceptible to steroid-induced hyperglycemia.
      While, MS patients commonly receive intravenous steroids, the clinical impact of any
      associated hyperglycemia is unknown.

      Study Design and Methods Timeline: Study will require 3 visits over a 6 month period.

      Subjects: MS subjects who are experiencing an acute relapse will be recruited for the study.
      Prior to any study procedures, the PI or research coordinator will obtain full written
      informed consent.

      Baseline Measurements: age, race/ethnicity, sex, weight, height, waist circumference, blood
      pressure, previous steroid exposure (dates, frequency, steroid type and dose), smoking
      history, and family history of diabetes. Medication review will include MS disease-modifying
      therapy, symptomatic medications, and non-MS-related medications. Additional MS-related
      information will include dates of initial MS-symptom onset, MS diagnosis, and onset of
      presenting relapse symptoms.

      Oral glucose tolerance test (OGTT) &amp; Matsuda Index: Prior to steroid administration, MS
      subjects will undergo a 2-hour OGTT. OGTT and Matsuda Index will then be repeated at the 3-
      and 6-month follow-up visits.

      Blood studies: HgA1c (hemoglobin A1C), a fasting lipid panel (LDL-C, HDL-C, triglycerides,
      and total cholesterol), insulin growth factor, vitamin D level, adiponectin level,
      homocysteine level, and leptin level. All laboratory tests completed at baseline, 3- and
      6-month visits.

      Surveys: Subjects will complete surveys related to their perceived disability, relapse
      severity and recovery, and other MS-related symptoms.

      Functional testing: EDSS, MS Functional Composite, timed-walk testing, accelerometry, low
      contrast visual acuity test (LCVA) and the symbol digit modality test (SDMT).

      Intravenous steroid treatment: Standardized 1000 mg of intravenous methylprednisolone (IVMP)
      daily for 3 days (reconstituted in 0.9% sodium chloride). IVMP will be billed to patient
      insurance as part of routine clinical care.

      Blood glucose monitoring: Bayer Contour Next glucometer will be used to measure capillary BG
      levels 6 times daily (Subjects will be instructed to check their BG starting on the day of
      screening and to continue BG checks (as above) until their return appointment 5-7 days after
      steroid treatment completion for a total of 8-10 days. Subjects will be required to avoid
      snacks between meals for the 3 days of IVMP treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse Recovery &amp; Hyperglycemia</measure>
    <time_frame>Recovery from relapse at 6-months</time_frame>
    <description>Determine the relationship between mean postprandial blood glucoses (BG) and relapse recovery (complete vs. incomplete) following a standardized IVMP treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin Resistance &amp; Relapse Severity</measure>
    <time_frame>At Baseline</time_frame>
    <description>Determine if insulin resistance (IR), measured by the Matsuda Index, is an independent predictor of relapse severity.</description>
  </primary_outcome>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <condition>Clinically Isolated Syndrome</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adults aged 18-54 (inclusive) with a diagnosis of clinically isolated syndrome or relapsing
        remitting multiple sclerosis with an acute attack (relapse).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide informed consent

          -  Age 18 -59 years (inclusive)

          -  Ability to walk continuously for 6 minutes (per patient report)

          -  Clinically Isolated Syndrome (CIS) or Relapsing Remitting MS (RRMS) confirmed
             diagnosis by McDonald 2010 criteria

               -  Current MS relapse with objective findings on exam

               -  Relapse symptom onset within 2-weeks of screening

               -  Functional System Scores obtainable from a clinic visit within 6 months of the
                  relapse assessment visit

               -  EDSS &lt; 6.5 at time of screening visit

               -  Inpatient, outpatient, emergency department, or inpatient observation status

        Exclusion Criteria:

          -  Prior steroid exposure within 90 days of enrollment

          -  HgA1c ≥ 6.5 at baseline screening

          -  Evidence of concurrent infection

          -  Known contraindications to IV steroid treatment

          -  History of diabetes mellitus ( type 1 or 2) or severe hypertension

          -  Use of any glucose-regulating medications

          -  Pregnancy or current use of hormone replacement therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myla Goldman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Myla Goldman, MD</last_name>
    <phone>434-243-6069</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rachael Coleman, MPH</last_name>
    <phone>434-297-4102</phone>
    <email>rcoleman@virginia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachael Coleman, MPH</last_name>
      <phone>434-297-4102</phone>
      <email>rcoleman@virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Myla Goldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Nickerson M, Marrie RA. The multiple sclerosis relapse experience: patient-reported outcomes from the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry. BMC Neurol. 2013 Sep 10;13:119. doi: 10.1186/1471-2377-13-119.</citation>
    <PMID>24016260</PMID>
  </reference>
  <reference>
    <citation>Hirst C, Ingram G, Pearson O, Pickersgill T, Scolding N, Robertson N. Contribution of relapses to disability in multiple sclerosis. J Neurol. 2008 Feb;255(2):280-7. doi: 10.1007/s00415-008-0743-8. Epub 2008 Jan 23.</citation>
    <PMID>18204919</PMID>
  </reference>
  <reference>
    <citation>Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology. 2003 Dec 9;61(11):1528-32.</citation>
    <PMID>14663037</PMID>
  </reference>
  <reference>
    <citation>Kwon S, Hermayer KL. Glucocorticoid-induced hyperglycemia. Am J Med Sci. 2013 Apr;345(4):274-7. doi: 10.1097/MAJ.0b013e31828a6a01. Review.</citation>
    <PMID>23531958</PMID>
  </reference>
  <reference>
    <citation>Johnston KC, Hall CE, Kissela BM, Bleck TP, Conaway MR; GRASP Investigators. Glucose Regulation in Acute Stroke Patients (GRASP) trial: a randomized pilot trial. Stroke. 2009 Dec;40(12):3804-9. doi: 10.1161/STROKEAHA.109.561498. Epub 2009 Oct 15.</citation>
    <PMID>19834016</PMID>
  </reference>
  <reference>
    <citation>Baker L, Juneja R, Bruno A. Management of hyperglycemia in acute ischemic stroke. Curr Treat Options Neurol. 2011 Dec;13(6):616-28. doi: 10.1007/s11940-011-0143-8.</citation>
    <PMID>21861124</PMID>
  </reference>
  <reference>
    <citation>Southerland AM, Johnston KC. Considering hyperglycemia and thrombolysis in the Stroke Hyperglycemia Insulin Network Effort (SHINE) trial. Ann N Y Acad Sci. 2012 Sep;1268:72-8. doi: 10.1111/j.1749-6632.2012.06731.x. Review.</citation>
    <PMID>22994224</PMID>
  </reference>
  <reference>
    <citation>Bruno A, Biller J, Adams HP Jr, Clarke WR, Woolson RF, Williams LS, Hansen MD. Acute blood glucose level and outcome from ischemic stroke. Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Neurology. 1999 Jan 15;52(2):280-4.</citation>
    <PMID>9932944</PMID>
  </reference>
  <reference>
    <citation>Fang Y, Zhang S, Wu B, Liu M. Hyperglycaemia in acute lacunar stroke: a Chinese hospital-based study. Diab Vasc Dis Res. 2013 May;10(3):216-21. doi: 10.1177/1479164112459663. Epub 2012 Oct 18.</citation>
    <PMID>23079541</PMID>
  </reference>
  <reference>
    <citation>Matute C, Domercq M, Pérez-Samartín A, Ransom BR. Protecting white matter from stroke injury. Stroke. 2013 Apr;44(4):1204-11. doi: 10.1161/STROKEAHA.112.658328. Epub 2012 Dec 4. Review.</citation>
    <PMID>23212168</PMID>
  </reference>
  <reference>
    <citation>Wens I, Dalgas U, Deckx N, Cools N, Eijnde BO. Does multiple sclerosis affect glucose tolerance? Mult Scler. 2014 Aug;20(9):1273-6. doi: 10.1177/1352458513515957. Epub 2013 Dec 17.</citation>
    <PMID>24347183</PMID>
  </reference>
  <reference>
    <citation>Sternberg Z, Leung C, Sternberg D, Li F, Karmon Y, Chadha K, Levy E. The prevalence of the classical and non-classical cardiovascular risk factors in multiple sclerosis patients. CNS Neurol Disord Drug Targets. 2013 Feb 1;12(1):104-11.</citation>
    <PMID>23244431</PMID>
  </reference>
  <reference>
    <citation>Marrie RA, Rudick R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology. 2010 Mar 30;74(13):1041-7. doi: 10.1212/WNL.0b013e3181d6b125.</citation>
    <PMID>20350978</PMID>
  </reference>
  <reference>
    <citation>Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology. 2009 Jan 13;72(2):117-24. doi: 10.1212/01.wnl.0000333252.78173.5f. Epub 2008 Oct 29.</citation>
    <PMID>18971448</PMID>
  </reference>
  <reference>
    <citation>Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology. 1998 Aug;51(2):529-34.</citation>
    <PMID>9710030</PMID>
  </reference>
  <reference>
    <citation>Eriksson M, Andersen O, Runmarker B. Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler. 2003 Jun;9(3):260-74. Erratum in: Mult Scler. 2003 Dec;9(6):641.</citation>
    <PMID>12814173</PMID>
  </reference>
  <reference>
    <citation>Langer-Gould A, Popat RA, Huang SM, Cobb K, Fontoura P, Gould MK, Nelson LM. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol. 2006 Dec;63(12):1686-91. Review.</citation>
    <PMID>17172607</PMID>
  </reference>
  <reference>
    <citation>Marrie RA, Horwitz R, Cutter G, Tyry T. Cumulative impact of comorbidity on quality of life in MS. Acta Neurol Scand. 2012 Mar;125(3):180-6. doi: 10.1111/j.1600-0404.2011.01526.x. Epub 2011 May 26.</citation>
    <PMID>21615355</PMID>
  </reference>
  <reference>
    <citation>Godoy DA, Di Napoli M, Rabinstein AA. Treating hyperglycemia in neurocritical patients: benefits and perils. Neurocrit Care. 2010 Dec;13(3):425-38. doi: 10.1007/s12028-010-9404-8. Review.</citation>
    <PMID>20652767</PMID>
  </reference>
  <reference>
    <citation>Sala F, Menna G, Bricolo A, Young W. Role of glycemia in acute spinal cord injury. Data from a rat experimental model and clinical experience. Ann N Y Acad Sci. 1999;890:133-54.</citation>
    <PMID>10668421</PMID>
  </reference>
  <reference>
    <citation>Zhao QJ, Zhang XG, Wang LX. Mild hypothermia therapy reduces blood glucose and lactate and improves neurologic outcomes in patients with severe traumatic brain injury. J Crit Care. 2011 Jun;26(3):311-5. doi: 10.1016/j.jcrc.2010.08.014. Epub 2010 Oct 2.</citation>
    <PMID>20889287</PMID>
  </reference>
  <reference>
    <citation>Selwyn R, Hockenbury N, Jaiswal S, Mathur S, Armstrong RC, Byrnes KR. Mild traumatic brain injury results in depressed cerebral glucose uptake: An (18)FDG PET study. J Neurotrauma. 2013 Dec 1;30(23):1943-53. doi: 10.1089/neu.2013.2928. Epub 2013 Oct 2.</citation>
    <PMID>23829400</PMID>
  </reference>
  <reference>
    <citation>Johnston KC, Connors AF Jr, Wagner DP, Knaus WA, Wang X, Haley EC Jr. A predictive risk model for outcomes of ischemic stroke. Stroke. 2000 Feb;31(2):448-55.</citation>
    <PMID>10657421</PMID>
  </reference>
  <reference>
    <citation>Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S; ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004 Mar 6;363(9411):768-74.</citation>
    <PMID>15016487</PMID>
  </reference>
  <reference>
    <citation>Vespa P, McArthur DL, Stein N, Huang SC, Shao W, Filippou M, Etchepare M, Glenn T, Hovda DA. Tight glycemic control increases metabolic distress in traumatic brain injury: a randomized controlled within-subjects trial. Crit Care Med. 2012 Jun;40(6):1923-9. doi: 10.1097/CCM.0b013e31824e0fcc.</citation>
    <PMID>22610193</PMID>
  </reference>
  <reference>
    <citation>Moro N, Ghavim S, Harris NG, Hovda DA, Sutton RL. Glucose administration after traumatic brain injury improves cerebral metabolism and reduces secondary neuronal injury. Brain Res. 2013 Oct 16;1535:124-36. doi: 10.1016/j.brainres.2013.08.044. Epub 2013 Aug 29.</citation>
    <PMID>23994447</PMID>
  </reference>
  <reference>
    <citation>Nijland PG, Michailidou I, Witte ME, Mizee MR, van der Pol SM, van Het Hof B, Reijerkerk A, Pellerin L, van der Valk P, de Vries HE, van Horssen J. Cellular distribution of glucose and monocarboxylate transporters in human brain white matter and multiple sclerosis lesions. Glia. 2014 Jul;62(7):1125-41. doi: 10.1002/glia.22667. Epub 2014 Apr 1.</citation>
    <PMID>24692237</PMID>
  </reference>
  <reference>
    <citation>Bruno A, Kent TA, Coull BM, Shankar RR, Saha C, Becker KJ, Kissela BM, Williams LS. Treatment of hyperglycemia in ischemic stroke (THIS): a randomized pilot trial. Stroke. 2008 Feb;39(2):384-9. Epub 2007 Dec 20.</citation>
    <PMID>18096840</PMID>
  </reference>
  <reference>
    <citation>Pulsinelli WA, Levy DE, Sigsbee B, Scherer P, Plum F. Increased damage after ischemic stroke in patients with hyperglycemia with or without established diabetes mellitus. Am J Med. 1983 Apr;74(4):540-4.</citation>
    <PMID>6837584</PMID>
  </reference>
  <reference>
    <citation>Lassmann H. Hypoxia-like tissue injury as a component of multiple sclerosis lesions. J Neurol Sci. 2003 Feb 15;206(2):187-91. Review.</citation>
    <PMID>12559509</PMID>
  </reference>
  <reference>
    <citation>Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology. 2001 Oct 9;57(7):1239-47.</citation>
    <PMID>11591843</PMID>
  </reference>
  <reference>
    <citation>Viardot A, Grey ST, Mackay F, Chisholm D. Potential antiinflammatory role of insulin via the preferential polarization of effector T cells toward a T helper 2 phenotype. Endocrinology. 2007 Jan;148(1):346-53. Epub 2006 Sep 28.</citation>
    <PMID>17008395</PMID>
  </reference>
  <reference>
    <citation>Wieser V, Moschen AR, Tilg H. Inflammation, cytokines and insulin resistance: a clinical perspective. Arch Immunol Ther Exp (Warsz). 2013 Apr;61(2):119-25. doi: 10.1007/s00005-012-0210-1. Epub 2013 Jan 10. Review.</citation>
    <PMID>23307037</PMID>
  </reference>
  <reference>
    <citation>Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006 Jul;116(7):1793-801. Review. Erratum in: J Clin Invest. 2006 Aug;116(8):2308.</citation>
    <PMID>16823477</PMID>
  </reference>
  <reference>
    <citation>Kallaur AP, Oliveira SR, Colado Simão AN, Delicato de Almeida ER, Kaminami Morimoto H, Lopes J, de Carvalho Jennings Pereira WL, Marques Andrade R, Muliterno Pelegrino L, Donizete Borelli S, Kaimen-Maciel DR, Reiche EM. Cytokine profile in relapsing‑remitting multiple sclerosis patients and the association between progression and activity of the disease. Mol Med Rep. 2013 Mar;7(3):1010-20. doi: 10.3892/mmr.2013.1256. Epub 2013 Jan 2.</citation>
    <PMID>23292766</PMID>
  </reference>
  <reference>
    <citation>Rudick RA, Ransohoff RM. Cytokine secretion by multiple sclerosis monocytes. Relationship to disease activity. Arch Neurol. 1992 Mar;49(3):265-70.</citation>
    <PMID>1536629</PMID>
  </reference>
  <reference>
    <citation>Khalili M, Azimi A, Izadi V, Eghtesadi S, Mirshafiey A, Sahraian MA, Motevalian A, Norouzi A, Sanoobar M, Eskandari G, Farhoudi M, Amani F. Does lipoic acid consumption affect the cytokine profile in multiple sclerosis patients: a double-blind, placebo-controlled, randomized clinical trial. Neuroimmunomodulation. 2014;21(6):291-6. doi: 10.1159/000356145. Epub 2014 May 6.</citation>
    <PMID>24821457</PMID>
  </reference>
  <reference>
    <citation>Imitola J, Chitnis T, Khoury SJ. Cytokines in multiple sclerosis: from bench to bedside. Pharmacol Ther. 2005 May;106(2):163-77. Epub 2005 Jan 11. Review.</citation>
    <PMID>15866318</PMID>
  </reference>
  <reference>
    <citation>Schneider A, Long SA, Cerosaletti K, Ni CT, Samuels P, Kita M, Buckner JH. In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive T(regs) involves IL-6-mediated signaling. Sci Transl Med. 2013 Jan 30;5(170):170ra15. doi: 10.1126/scitranslmed.3004970.</citation>
    <PMID>23363979</PMID>
  </reference>
  <reference>
    <citation>Warabi Y. Role of IL-1 and potential therapies in multiple sclerosis. Drug Discovery Today: Therapeutic Strategies 2007;4:19-24.</citation>
  </reference>
  <reference>
    <citation>Juhler M. Simultaneous determination of regional cerebral blood flow, glucose metabolism, and pH in acute experimental allergic encephalomyelitis. J Cereb Blood Flow Metab. 1987 Oct;7(5):578-84.</citation>
    <PMID>3654798</PMID>
  </reference>
  <reference>
    <citation>Juhler M. Pathophysiological aspects of acute experimental allergic encephalomyelitis. Acta Neurol Scand Suppl. 1988;119:1-21. Review.</citation>
    <PMID>3064529</PMID>
  </reference>
  <reference>
    <citation>JONES HH, JONES HH Jr, BUNCH LD. Biochemical studies in multiple sclerosis. Ann Intern Med. 1950 Oct;33(4):831-40.</citation>
    <PMID>14771754</PMID>
  </reference>
  <reference>
    <citation>Sternberg Z, Leung C, Sternberg D, Yu J, Hojnacki D. Disease modifying therapies modulate cardiovascular risk factors in patients with multiple sclerosis. Cardiovasc Ther. 2014 Apr;32(2):33-9. doi: 10.1111/1755-5922.12049.</citation>
    <PMID>24119301</PMID>
  </reference>
  <reference>
    <citation>Mowry EM, Pesic M, Grimes B, Deen S, Bacchetti P, Waubant E. Demyelinating events in early multiple sclerosis have inherent severity and recovery. Neurology. 2009 Feb 17;72(7):602-8. doi: 10.1212/01.wnl.0000342458.39625.91.</citation>
    <PMID>19221292</PMID>
  </reference>
  <reference>
    <citation>Penesova A, Vlcek M, Imrich R, Vernerova L, Marko A, Meskova M, Grunnerova L, Turcani P, Jezova D, Kollar B. Hyperinsulinemia in newly diagnosed patients with multiple sclerosis. Metab Brain Dis. 2015 Aug;30(4):895-901. doi: 10.1007/s11011-015-9665-1. Epub 2015 Mar 27.</citation>
    <PMID>25809135</PMID>
  </reference>
  <reference>
    <citation>SCHUMACHER GA, BEEBE G, KIBLER RF, KURLAND LT, KURTZKE JF, MCDOWELL F, NAGLER B, SIBLEY WA, TOURTELLOTTE WW, WILLMON TL. PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS. Ann N Y Acad Sci. 1965 Mar 31;122:552-68.</citation>
    <PMID>14313512</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2016</study_first_submitted>
  <study_first_submitted_qc>December 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2016</study_first_posted>
  <last_update_submitted>January 6, 2017</last_update_submitted>
  <last_update_submitted_qc>January 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Myla Goldman, MD</investigator_full_name>
    <investigator_title>Associate Professor of the Department of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

